

BOARD UPDATE AT ATLEY SOLUTIONS - ERIK STRÖMQVIST APPOINTED CHAIRMAN OF THE BOARD

Gothenburg, Sweden – September 2025 – Following their most recent investment round, Atley Solutions announces changes to its Board of Directors, strengthening governance and industry expertise to support the company's next phase of growth.

Erik Strömqvist, who has previously served as a member of Atley's Board of Directors, has now been appointed Chairman of the Board. Erik spent 5 years as Global Engineering Manager - Radiopharmacy, followed by 11 years as global General Manager – Cyclotrons at GE Healthcare. He now holds Board Member and Chairperson positions at notable companies within and outside of Nuclear Medicine including MedTrace Pharma, Studsvik, and XVIVO. With this extensive experience in nuclear medicine and global radiopharmaceutical manufacturing, Erik is well positioned to help guide Atley's continued growth and international expansion.

We extend our sincere thanks to Fredrik Bergman, who has served as Chairman since the company's incorporation. His leadership has been instrumental in shaping Atley's early trajectory. Fredrik will remain on the Board and continue to contribute to the company's strategic development.

We are also proud to welcome **Johanna Asklin**, General Partner at FSG, as a new Board Member. Johanna brings more than 15 years of international experience in strategy and business development across diagnostics and therapeutics.

Finally, we thank Mattias Münnich and Sture Lindegren for their important contributions as board members. While both are stepping down from the board, they will remain actively involved in the company in other capacities.

We look forward to this next chapter, guided by a strengthened board and united in our mission to transform cancer treatment with Astatine-211.

About Atley Solutions

Atley Solutions is the global leader in commercial products and services for the development, clinical evaluation and commercialisation of At-211 radiopharmaceuticals. The Atley C100 is the world's only commercial module for automated manufacturing of At-211 radiopharmaceuticals, addressing key challenges in radionuclide production and supply chain scalability. In addition to its cutting-edge technology, Atley provides radiopharmaceutical development services and products related to the production of the isotope At-211.

Contact Information

For more information please contact:

Milton Lönnroth

Co-Founder & CEO

Atley Solutions AB

Phone: +46 (0) 704 34 84 57

Email: info@atley.com